Emerging as a new frontier in heterogeneous catalysis, single-atom site catalysts (SSCs) have sparked enormous attention and bring about new opportunities to oxygen reduction electrocatalysis. Despite considerable progress achieved recently, most of the reported SSCs suffer from either insufficient activity or unsatisfactory stability, which severely retards their practical application. Here, we demonstrate a novel Ru-SSC with appropriate adsorption free energy of OH* (ΔG OH*) to confer excellent activity and low Fenton reactivity to maintain long-term stability. The as-developed Ru-SSC exhibits encouraging oxygen reduction reaction turnover frequency of 4.99 e– s–1 sites–1, far exceeding the state-of-the-art Fe-SSC counterpart (0.816 e– s–1 sites–1), as a result of Ru energy level regulation via spontaneous OH binding. Furthermore, Ru-SSC exhibits greatly suppressed Fenton reactivity, with restrained generation of reactive oxygen species directly observed, thus endowing the Ru-SSC with much more superior stability (only 17 mV negative shift after 20 000 cycles) than the Fe-SSC counterpart (31 mV). The practical application of Ru-SSC is further validated by its excellent activity and stability in a real fuel cell device.

No abstract

Metabolomics seeks to take a "snapshot" in a time of the levels, activities, regulation and interactions of all small molecule metabolites in response to a biological system with genetic or environmental changes. The emerging development in mass spectrometry technologies has shown promise in the discovery and quantitation of neuroactive small molecule metabolites associated with gut microbiota and brain. Significant progress has been made recently in the characterization of intermediate role of small molecule metabolites linked to neural development and neurodegenerative disorder, showing its potential in understanding the crosstalk between gut microbiota and the host brain. More evidence reveals that small molecule metabolites may play a critical role in mediating microbial effects on neurotransmission and disease development. Mass spectrometry-based metabolomics is uniquely suitable for obtaining the metabolic signals in bidirectional communication between gut microbiota and brain. In this review, we summarized major mass spectrometry technologies including liquid chromatography-mass spectrometry, gas chromatography-mass spectrometry, and imaging mass spectrometry for metabolomics studies of neurodegenerative disorders. We also reviewed the recent advances in the identification of new metabolites by mass spectrometry and metabolic pathways involved in the connection of intestinal microbiota and brain. These metabolic pathways allowed the microbiota to impact the regular function of the brain, which can in turn affect the composition of microbiota via the neurotransmitter substances. The dysfunctional interaction of this crosstalk connects neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease and Huntington's disease. The mass spectrometry-based metabolomics analysis provides information for targeting dysfunctional pathways of small molecule metabolites in the development of the neurodegenerative diseases, which may be valuable for the investigation of underlying mechanism of therapeutic strategies.

A single crystal of Bi2ZnOB2O6 has been grown with sizes up to 18 × 13 × 6 mm3 by the top-seeded growth method for the first time with high quality. It crystallizes in the orthorhombic system, space group Pba2 with unit-cell parameters a = 10.8200(7) Å, b = 11.0014(7) Å, c = 4.8896(3) Å, Z = 4, V = 582.03(6) Å3. Bi2ZnOB2O6 has a three-dimensional network consisting of ZnB2O7 6- layers alternating with six-coordinated Bi3+ cations along the c axis. Transmission spectrum of Bi2ZnOB2O6 crystal was reported. The refractive indices of the crystal were measured by the minimum deviation technique and fitted to the Sellmeier equations. The powder second-harmonic generation (SHG) properties measured by the Kurtz−Perry method indicate that Bi2ZnOB2O6 is phase-matchable.